Leflunomide

This classification denotes a pyrimidine antagonist and dihydroorotate dehydrogenase inhibitor and angiogenesis activator inhibitor with the molecular formula C12H9F3N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) G162GK9U4W, chemically known as 4-isoxazolecarboxamide, 5-methyl-n-(4-(trifluoromethyl)phenyl but more generally known as leflunomide, which bears US NIH Compound Identifier 3899. European Medicines Agency schedules Leflunomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08424MIG. The term LEFLUNOMIDE is an International Non-Proprietary Name. World Health Organization schedules leflunomide in its Anatomical Therapeutic Chemical (ATC) Classification. LEFLUNOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule leflunomide under HS 29349990 and SITC 51579. As of Q4 2014, LEFLUNOMIDE remains US FDA's Preferred Term for this commodity. Leflunomide bears US NLM identifiers UMLS ID C0718644 and NCI Concept Code C1128. SMILES: FC(F)(F)C1CCC(NC(=O)C2C(ONC2)C)CC1.